CAMBRIDGE, Mass., July 23 /PRNewswire/ -- Genstruct Inc., a biotechnology company translating the complexity of human biology to develop new successful therapeutics, announced today that Christopher Z. Thomajan has joined the company as its new chief financial officer. In this position, Mr. Thomajan’s primary responsibilities are to oversee the company’s day-to-day financial and investor relations activities and longer term growth strategies.
“Chris brings with him an extensive background in financial and senior management positions, with companies like Asurion, Celadon Science and America’s Growth Capital. We expect that his varied expertise guiding technology companies and building financial institutions will be a great value add for Genstruct, and that he will play a critical role in the achievement of our future financial goals,” stated Dr. Keith O. Elliston, president and CEO at Genstruct. “I am excited to have Chris as a part of Genstruct’s management team and look forward to working with him to map out Genstruct’s future.”
Mr. Thomajan joins Genstruct with more than 18 years of experience in the areas of finance and management. Mr. Thomajan has worked as chief financial officer for companies such as Delphi Internet Services Corporation, Asurion Corporation, Celadon Science, LLC and American’s Growth Capital, LLC. Most recently he served as chief financial officer for Impress Software, Inc., where he was an integral part in expanding this German company’s U.S.-based operations. During his tenure, he helped Impress double their sales, raising equity rounds totaling $17 million.
Mr. Thomajan also established a $2 million bank line of credit, and managed the finance, HR and customer support departments for this global organization. Mr. Thomajan received his undergraduate education from Dartmouth College and his graduate degree from Columbia University’s Graduate School of Business.
About Genstruct
Founded in 2002, Genstruct is a biotechnology company focused on elucidating the complexity of biology for the development of successful therapeutics. By modeling the components within the whole biological system, Genstruct delivers a deep molecular understanding of diseases and drug action, as well as mechanistic biomarkers to accelerate drug discovery and development programs. Genstruct engages in internal discovery and external development partnerships with top tier pharmaceutical companies, which apply systems biology in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. The privately held company is based in Cambridge, Mass. For more information, please visit www.genstruct.com.
Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.
Karen Higgins A & E Communications for Genstruct (610) 831-5723 khiggins@aandecomm.com
Genstruct Inc.
CONTACT: Karen Higgins of A & E Communications, +1-610-831-5723,khiggins@aandecomm.com, for Genstruct
Web site: http://www.genstruct.com//